首页> 外国专利> Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress

Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress

机译:针对蛋白质合成应激的肿瘤适应性反应的癌症治疗

摘要

In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
机译:在诸如前列腺癌的癌症中,PTEN丢失和Myc激活的组合激活了一种适应性应激反应,使肿瘤细胞能够逃避大规模上调蛋白质合成的压力。该存活前应答由UPR适应性应答的PERK磷酸化的eIF2α轴介导。破坏PERK-eIF2α途径的药物破坏了适应性反应,并导致癌细胞由于不受控制的生长而死亡。例如,ISRIB及其衍生物可用作治疗剂以破坏PERK介导的适应性机制。此外,PTEN的丢失和Myc的激活提供了一种诊断标记,可以更好地预后并选择合适的治疗方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号